ROY S. HERBST, M.D., PHD
Osteopathic Medicine at Holcombe Blvd, Houston, TX
License number
Texas K4457
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991
(713) 792-2991
Personal information
See more information about ROY S. HERBST at radaris.comName
Address
Phone
6429 Sewanee Ave, Houston, TX 77005
3121 Buffalo Speedway, Houston, TX 77098
7300 Brompton St, Houston, TX 77025
Professional information
See more information about ROY S. HERBST at trustoria.com
Dr. Roy S Herbst, New Haven CT - MD (Doctor of Medicine)
Dr. Roy S Herbst, New Haven CT - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
333 Cedar St, New Haven 06510
(203) 785-4095 (Phone), (203) 737-5698 (Fax)
YALE CANCER CENTER
333 Cedar St SUITE 208032, New Haven 06510
(203) 737-5312 (Phone), (203) 785-3788 (Fax)
YALE THORACIC ONCOLOGY PROGRAM
330 Cedar St, New Haven 06510
(203) 200-5864 (Phone)
(203) 785-4095 (Phone), (203) 737-5698 (Fax)
YALE CANCER CENTER
333 Cedar St SUITE 208032, New Haven 06510
(203) 737-5312 (Phone), (203) 785-3788 (Fax)
YALE THORACIC ONCOLOGY PROGRAM
330 Cedar St, New Haven 06510
(203) 200-5864 (Phone)
Certifications:
Internal Medicine, 1994, Medical Oncology, 2007
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
333 Cedar St, New Haven 06510
YALE THORACIC ONCOLOGY PROGRAM
330 Cedar St, New Haven 06510
YALE CANCER CENTER
333 Cedar St SUITE 208032, New Haven 06510
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
YALE THORACIC ONCOLOGY PROGRAM
330 Cedar St, New Haven 06510
YALE CANCER CENTER
333 Cedar St SUITE 208032, New Haven 06510
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
Education:
Medical School
Weill Cornell Medical College
Graduated: 1991
Brigham and Womens Hospital
Dana Farber Cancer Inst
Weill Cornell Medical College
Graduated: 1991
Brigham and Womens Hospital
Dana Farber Cancer Inst
Roy Steven Herbst, Houston TX
Roy Steven Herbst, Houston TX
Specialties:
Internal Medicine, Medical Oncology, Hematology & Oncology, Hematology
Work:
M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX 77030 M D Anderson Cancer Ctr
1400 Holcombe Blvd, Houston, TX 77030
1515 Holcombe Blvd, Houston, TX 77030 M D Anderson Cancer Ctr
1400 Holcombe Blvd, Houston, TX 77030
Education:
Cornell University (1991)
Roy S Herbst, Houston TX
Roy S Herbst, Houston TX
Specialties:
Oncologist
Address:
1515 Holcombe Blvd, Houston, TX 77030
333 Cedar St, New Haven, CT 06510
333 Cedar St, New Haven, CT 06510
Education:
Cornell University, Weill Cornell Medical College - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Compositions And Methods For Treating Lung Cancer
Compositions And Methods For Treating Lung Cancer
US Patent:
2011009, Apr 21, 2011
Filed:
Feb 13, 2009
Appl. No.:
12/866877
Inventors:
Garth Powis - Houston TX, US
Roy Herbst - Houston TX, US
Jörg Jacoby - The Woodlands TX, US
Roy Herbst - Houston TX, US
Jörg Jacoby - The Woodlands TX, US
International Classification:
A61K 31/195, A61P 35/00
US Classification:
514567
Abstract:
Embodiments of the present invention provide compositions and methods for treating lung cancer, including small cell and non-small cell lung cancer that may express HIF-1a by administering a therapeutically effective amount of PX-478.
Biomarkers For Response To Tyrosine Kinase Pathway Inhibitors In Cancer
Biomarkers For Response To Tyrosine Kinase Pathway Inhibitors In Cancer
US Patent:
2013023, Sep 5, 2013
Filed:
Feb 4, 2013
Appl. No.:
13/758728
Inventors:
Ignacio I. WISTUBA - Houston TX, US
Monique B. NILSSON - Sugar Land TX, US
Lauren A. BYERS - Houston TX, US
Ximing TANG - Houston TX, US
Fei YANG - Houston TX, US
Edward KIM - Houston TX, US
Anne S. TSAO - Houston TX, US
Scott M. LIPPMAN - Houston TX, US
Waun Ki HONG - Houston TX, US
Roy S. HERBST - Houston TX, US
Monique B. NILSSON - Sugar Land TX, US
Lauren A. BYERS - Houston TX, US
Ximing TANG - Houston TX, US
Fei YANG - Houston TX, US
Edward KIM - Houston TX, US
Anne S. TSAO - Houston TX, US
Scott M. LIPPMAN - Houston TX, US
Waun Ki HONG - Houston TX, US
Roy S. HERBST - Houston TX, US
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
G01N 33/74, A61K 39/395, A61K 31/506, A61K 31/4439, C12Q 1/68, A61K 31/4045
US Classification:
4241331, 435 723, 435 611, 514414, 51425218, 514338
Abstract:
Copy number gains detected in tumors and associated with drug sensitivity and resistance in vivo and in vitro can be used as biomarkers to select, predict and monitor drug treatment outcomes in cancer patients treated with tyrosine kinase inhibitors. Methods to identify patients with NSCLC or other malignancies who are more likely to benefit from tyrosine kinase inhibitors such as VEGF or VEGFR inhibitors when used either as monotherapy or in combination with other therapies such as chemotherapy or EGFR inhibitors, and who are in the advanced stages of disease and/or who have undergone adjuvant therapy are also provided herein.